Acute SGLT2 Inhibition and the Pressure Natriuresis Response in Rats with Type 1 Diabetes

被引：0
|
作者：
Bailey, Matthew A.
Costello, Hannah M.
Stewart, Kevin
Binnie, David
Culshaw, Geoffrey C.
Webb, David J.
机构：
来源：
FASEB JOURNAL | 2019年 / 33卷
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
569.10
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Modeling Cardiorenal Protection with SGLT2 Inhibition in Type 1 Diabetes: An Analysis of DEPICT-1 and-2
    Nardone, Massimo
    Kugathasan, Luxcia
    Sridhar, Vikas
    Dutta, Pritha
    Campbell, David
    Layton, Anita T.
    Perkins, Bruce A.
    Barbour, Sean
    Lam, Tony K. T.
    Levin, Adeera
    Lovblom, Leif Erik
    Mucsi, Istvan
    Rabasa-Lhoret, Remi
    Rac, Valeria E.
    Senior, Peter A.
    Sigal, Ronald J.
    Stanimirovic, Aleksandra
    Doria, Alessandro
    Cherney, David
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 35 (10):
  • [42] SGLT2 Inhibition Increases Serum Copeptin in Adults with Type 1 Diabetes (T1D)
    Lytvyn, Yuliya
    Bjornstad, Petter
    Katz, Alexandra
    Singh, Sunita K.
    Godoy, Lucas C.
    Chung, Linh T.
    Vinovskis, Carissa L.
    Perkins, Bruce A.
    Cherney, David
    DIABETES, 2019, 68
  • [43] Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration
    Marko Škrtić
    Gary K. Yang
    Bruce A. Perkins
    Nima Soleymanlou
    Yuliya Lytvyn
    Maximilian von Eynatten
    Hans J. Woerle
    Odd Erik Johansen
    Uli C. Broedl
    Thomas Hach
    Melvin Silverman
    David Z. I. Cherney
    Diabetologia, 2014, 57 : 2599 - 2602
  • [44] Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration
    Skrtic, Marko
    Yang, Gary K.
    Perkins, Bruce A.
    Soleymanlou, Nima
    Lytvyn, Yuliya
    von Eynatten, Maximilian
    Woerle, Hans J.
    Johansen, Odd Erik
    Broedl, Uli C.
    Hach, Thomas
    Silverman, Melvin
    Cherney, David Z. I.
    DIABETOLOGIA, 2014, 57 (12) : 2599 - 2602
  • [45] Correction to: Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes
    Marc Evans
    Debbie Hicks
    Dipesh Patel
    Vinod Patel
    Phil McEwan
    Umesh Dashora
    Diabetes Therapy, 2020, 11 : 571 - 571
  • [46] SGLT1 does compensate for SGLT2 inhibition
    Javier Martinez-Martin, Francisco
    Jimenez-Martin, Natalia
    Sablon-Gonzalez, Nery
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2016, 2 (04) : 256 - 256
  • [47] Better response to the SGLT2 inhibitor dapagliflozin in young adults with type 2 diabetes
    Nakamura, Yuta
    Nagai, Yoshio
    Terashima, Yuko
    Nishine, Ami
    Ishii, Satoshi
    Kato, Hiroyuki
    Ohta, Akio
    Tanaka, Yasushi
    EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (17) : 2553 - 2559
  • [48] Investigational Agents Targeting SGLT1 and SGLT2 in the Treatment of Type 2 Diabetes Mellitus
    Cui, Haigang
    Luo, Xin
    Chen, Mingwei
    Lu, Jun
    Liu, Johnson J. J.
    CURRENT DRUG TARGETS, 2023, 24 (08) : 648 - 661
  • [49] The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus
    Pitt, Bertram
    Steg, Gabriel
    Leiter, Lawrence A.
    Bhatt, Deepak L.
    CARDIOVASCULAR DRUGS AND THERAPY, 2022, 36 (03) : 561 - 567
  • [50] Randomized Trial Comparing SGLT2 Inhibition and Hydrochlorothiazide on Sympathetic Traffic in Type 2 Diabetes
    Heusser, Karsten
    Tank, Jens
    Diedrich, Andre
    Fischer, Annelie
    Heise, Tim
    Jordan, Jens
    KIDNEY INTERNATIONAL REPORTS, 2023, 8 (11): : 2254 - 2264
12345